| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1b data readout example | SGT-212 (gene therapy for Friedreich’s ataxia) Friedreich’s ataxia | Phase 1b | — | Gene Therapies | Rare Diseases | ||
phase 1b data readout example | SGT-212 (gene therapy for Friedreich’s ataxia) Friedreich’s ataxia | Phase 1b | — | Gene Therapies | Rare Diseases | ||
phase 1b data readout example | SGT-212 (gene therapy for Friedreich’s ataxia) Friedreich’s ataxia | Phase 1b | — | Gene Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
Solid Biosciences Inc.$9.01
+0.13 (+1.41%)
C 56Pipeline Score Undervalued Biotech · Clinical
Market Cap
651.74 M
EPS
-1.95
P/E Ratio
-
Value Trade
6.82 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
46.14 M
Operating CF
-47.23 M
Total Assets
422.89 M
Total Liabilities
48.76 M
Equity
374.13 M
D/E Ratio
12,345
-10.9 %
Week
-19.66 %
1 Month
14.53 %
3 Month
47.27 %
6 Month
-88.65 %
5 Year
-98.27 %
All Time
Cash Data
Cash Position
380.68 M
Monthly Burn
15.74 M
Runway
22.7 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
675.04 K
52 Week Range
2.83 - 8.87
% held by Insiders
20.57 %
% held by Institutions
82.89 %
Enterprise Value
291.08 M
Total Shares
98.47 M
Short %
14.85 %
Float Shares
76.52 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C56
Pipeline Score $2.0B
Pipeline ValueUndervalued
Valuation Signal7
Drugs Scored3.1x
rNPV / MCap Top 85%
Micro Cap (rank 137 of 905)
Percentile RankSolid Biosciences Inc. carries a moderate pipeline score (56/100), with $5.0B risk-adjusted pipeline value, led by IP in Small Cell Lung Cancer (Phase 3), across $69B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IP Small molecule | Small Cell Lung Cancer | Phase 3 | NCT00349492 | 46% | $3.1B | COMPLETED | 372 | - | - | Oct 1, 2013 | - | Dec 4, 2013 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SGT-003 | Duchenne Muscular Dystrophy | Phase 1/2 | 2025-08-13 | |||
SGT-003 | Duchenne Muscular Dystrophy | Phase 1/2 | 2025-08-13 | |||
SGT-003 | Duchenne Muscular Dystrophy | Phase 1/2 | 2025-08-13 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SLDB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SLDB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SLDB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SLDB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SLDB Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
SLDB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026
Solid Biosciences Inc. has announced the grant of 6,580 restricted stock units (RSUs) to a newly hired employee. This grant is part of the company's 2024 Inducement Stock Incentive Plan and is intended to incentivize the employee's acceptance of the job. The RSUs will vest over four years, contingent on the employee's continued service.
Read more →SLDBSolid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc. has announced its participation in two upcoming investor conferences in June 2026. The presentations will be made by President and CEO Bo Cumbo, showcasing the company's advancements in precision genetic medicines for rare neuromuscular and cardiac diseases. The live webcasts of the presentations will be accessible on the company's website for interested investors and stakeholders. This engagement aims to highlight Solid's commitment to innovative gene therapies and ongoing developments in its pipeline.
Read more →SLDBSolid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
Solid Biosciences reported its Q1 2026 financial results, highlighting significant advancements in its clinical trials for Duchenne muscular dystrophy and Friedreich's ataxia. The company has initiated the Phase 3 IMPACT DUCHENNE trial and received positive regulatory feedback from the EMA. Additionally, Solid maintains a robust cash position, supporting its ongoing development efforts.
Read more →SLDBSolid Biosciences Doses First Participant In Phase 3 Impact Duchenne Clinical Trial Evaluating SGT-003 In Duchenne Muscular Dystrophy
Solid Biosciences Doses First Participant In Phase 3 Impact Duchenne Clinical Trial Evaluating SGT-003 In Duchenne Muscular Dystrophy
Read more →SLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Solid Biosciences Inc. has announced the grant of 8,070 restricted stock units to a newly hired employee as part of its 2024 Inducement Stock Incentive Plan. This grant, which vests over four years, is intended to incentivize the new employee's acceptance of the position. The company continues to advance its pipeline of gene therapies targeting rare neuromuscular and cardiac diseases.
Read more →SLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4
Read more →SLDBSolid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
Solid Biosciences Inc. will present its largest scientific program at the 29th Annual Meeting of the ASGCT, featuring 16 presentations including 5 oral and 11 poster presentations. The event highlights the company's advancements in gene therapies for neuromuscular and cardiac diseases, showcasing their commitment to innovation and clinical development. CEO Bo Cumbo emphasized the significance of this meeting for Solid's growth and scientific rigor.
Read more →SLDBSolid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
Solid Biosciences has announced that the European Commission granted Orphan Drug Designation for SGT-003, aimed at treating Duchenne muscular dystrophy. This designation reflects the drug's potential to address significant unmet medical needs. SGT-003 is currently being evaluated in two clinical trials, INSPIRE DUCHENNE and IMPACT DUCHENNE, as part of a broader international development strategy.
Read more →SLDBSolid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Read more →SLDBSolid Biosciences Provides Interim Positive Clinical Update
Solid Biosciences Provides Interim Positive Clinical Update
Read more →SLDBSolid Biosciences Announces Oversubscribed $240 Million Private Placement
Solid Biosciences Inc. has announced a successful oversubscribed private placement, raising approximately $240 million from institutional investors. The financing will close on or about March 9, 2026, and will be used to advance the company's pipeline of genetic medicines targeting neuromuscular and cardiac diseases. The placement was priced to meet Nasdaq's minimum price requirement.
Read more →SLDBSolid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Solid Biosciences Inc. will present its investigational gene therapies SGT-003 and SGT-212 at the 2026 MDA Clinical & Scientific Conference in Orlando. The presentations will cover the Phase 1/2 study of SGT-003 for Duchenne muscular dystrophy and the investigational gene therapy SGT-212 for Friedreich’s ataxia. The conference will take place from March 8-11, 2026.
Read more →SLDBSolid Biosciences to Present at the 2026 Muscular Dystrophy Association MDA Clinical Scientific Conference
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association MDA Clinical Scientific Conference
Read more →SLDBSolid Biosciences Announces Oversubscribed 240 Million Private Placement
Solid Biosciences Announces Oversubscribed 240 Million Private Placement
Read more →SLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2026
Solid Biosciences Inc. has announced the grant of 17,600 restricted stock units (RSUs) to a newly hired employee, as part of its 2024 Inducement Stock Incentive Plan. The RSUs will vest over four years, contingent on the employee's continued service. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and underscores the company's commitment to attracting skilled professionals in the field of genetic medicine.
Read more →SLDBSolid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
Solid Biosciences has received positive feedback from the FDA regarding the design of its Phase 3 trial for SGT-003, a gene therapy for Duchenne muscular dystrophy. The trial, named IMPACT DUCHENNE, is set to begin participant dosing in Q1 2026. The company is also planning further discussions with the FDA to explore an accelerated approval pathway. The ongoing Phase 1/2 trial has shown SGT-003 to be generally well tolerated among participants.
Read more →SLDBSolid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Solid Biosciences Inc. will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. CEO Bo Cumbo will discuss the company's advancements in precision genetic medicines targeting neuromuscular and cardiac diseases. The presentation will be available via live webcast and archived for 30 days.
Read more →SLDBSolid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
Solid Biosciences has provided an optimistic outlook for 2026, highlighting progress in its neuromuscular and cardiac gene therapy pipelines. The company has initiated multiple clinical trials, including the Phase 1b FALCON trial for Friedreich's ataxia. Additionally, they have executed over 50 agreements for their next-generation capsid AAV-SLB101. CEO Bo Cumbo emphasized the commitment to advancing innovative therapies while addressing the needs of patients.
Read more →SLDBSolid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
Solid Biosciences has received FDA Orphan Drug designation for SGT-212, a gene therapy aimed at treating Friedreich's ataxia. The company has completed dosing the first participant in the Phase 1b FALCON trial, with initial data expected in the second half of 2026. This therapy employs a dual-route administration to address the disease's neurological and cardiac manifestations.
Read more →SLDBSolid Biosciences Doses First Participant in First in Class Phase 1b FALCON Trial Evaluating SGT-212 Dual Route Gene Therapy for the Treatment of Friedreich s Ataxia
Solid Biosciences Doses First Participant in First in Class Phase 1b FALCON Trial Evaluating SGT-212 Dual Route Gene Therapy for the Treatment of Friedreich s Ataxia
Read more →SLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 5, 2026
Solid Biosciences Inc. has announced the grant of 7,000 restricted stock units to a newly hired employee as part of its 2024 Inducement Stock Incentive Plan. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4) and will vest over four years. The company focuses on developing genetic therapies for neuromuscular and cardiac diseases.
Read more →SLDBSolid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Solid Biosciences Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company's President and CEO, Bo Cumbo, will provide insights into their ongoing efforts in developing precision genetic medicines for neuromuscular and cardiac diseases. Solid Biosciences boasts a range of gene therapy candidates, including those for Duchenne muscular dystrophy and other genetic cardiac diseases, signaling the company's commitment to innovation in this field.
Read more →SLDBSolid Biosciences Present 44th Annual JP Morgan Healthcare
Solid Biosciences Present 44th Annual JP Morgan Healthcare
Read more →SLDBSolid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U S Department of Health and Human Services
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U S Department of Health and Human Services
Read more →SLDBSolid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
Solid Biosciences Inc. will present its proprietary AAV-SLB101 and cardiac gene therapy pipeline at the CVCT Forum in Washington, D.C. The company's Chief Medical Officer and Head of Discovery will share insights through presentations and panel discussions. This event emphasizes the importance of collaboration in advancing clinical trials and regulatory processes for cardiovascular treatments.
Read more →SLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 1, 2025
Solid Biosciences Inc. has announced the grant of 23,284 restricted stock units (RSUs) to two new employees as part of its 2024 Inducement Stock Incentive Plan. The RSUs will vest over four years, contingent on the employees' continued service. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's strategy to enhance its workforce.
Read more →SLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. has announced the grant of 23,284 restricted stock units (RSUs) to two newly hired employees as part of its 2024 Inducement Stock Incentive Plan. The RSUs will vest over four years, contingent on the employees' continued service. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's strategy to attract skilled professionals in the field of genetic medicine.
Read more →SLDBSolid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Solid Biosciences has received FDA Rare Pediatric Disease designation for its gene therapy SGT-212, aimed at treating Friedreich's ataxia. This therapy uniquely utilizes dual routes of administration to deliver the frataxin gene. The company is also screening participants for its FALCON Phase 1b clinical trial. These designations may facilitate faster regulatory review and market access.
Read more →SLDBSolid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101
Solid Biosciences has entered a non-exclusive licensing agreement with Andelyn Biosciences for its next-generation capsid, AAV-SLB101. This collaboration aims to enhance gene therapy development by integrating AAV-SLB101 into Andelyn's AAV Curator® Platform. The capsid has shown positive safety data in pediatric trials for Duchenne muscular dystrophy, with Solid pursuing broad licensing opportunities.
Read more →SLDBSolid Biosciences Participate Upcoming Investor Conferences
Solid Biosciences Participate Upcoming Investor Conferences
Read more →SLDBSolid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
Solid Biosciences has been awarded the Innovation Passport for SGT-003, a gene therapy for Duchenne muscular dystrophy, under the UK's Innovative Licensing and Access Pathway. This designation aims to accelerate the therapy's market entry and enhance patient access. SGT-003 is currently undergoing clinical trials in multiple countries, with the potential to transform treatment for Duchenne patients.
Read more →SLDBSolid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions
Solid Biosciences reported positive interim results from its INSPIRE DUCHENNE trial for SGT-003, with 23 participants dosed and promising microdystrophin expression levels. The company plans to meet with the FDA in H1 2026 to discuss potential registrational pathways. Additionally, Solid has activated clinical trial sites for other programs targeting Friedreich's ataxia and catecholaminergic polymorphic ventricular tachycardia.
Read more →SLDBSolid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions - Duchenne (SGT-003): 23 participants have been dosed in t
Solid Biosciences has reported its Q3 2025 financial results and provided an update on the INSPIRE DUCHENNE trial, where 23 participants have been dosed with SGT-003. The treatment has shown encouraging safety and efficacy signals, including microdystrophin expression and early indicators of cardiac function normalization. The company aims to meet with the FDA in H1 2026 to discuss possible registrational pathways. Solid also plans to advance additional clinical trials for other candidates in its pipeline.
Read more →SLDBSolid Biosciences to Present at Upcoming Scientific Meetings
Solid Biosciences Inc. will present data from its neuromuscular and cardiac programs at the World Muscle Society and European Society of Gene & Cell Therapy annual congresses in October 2025. The presentations will showcase the potential of their innovative pipeline and proprietary capsid, AAV-SLB101. Following the conferences, the presentations will be accessible on their website.
Read more →SLDBSolid Biosciences Present Upcoming Scientific Meetings
Solid Biosciences Present Upcoming Scientific Meetings
Read more →SLDBSolid Biosciences Reports Inducement Grants Under Nasdaq
Solid Biosciences Reports Inducement Grants Under Nasdaq
Read more →SLDBSolid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting
Solid Biosciences will present data from the Phase 1/2 INSPIRE DUCHENNE trial for SGT-003 at the Neuromuscular Study Group Annual Meeting. The data includes updated safety information and previously reported biopsy results. The company highlights the favorable profile of SGT-003, particularly its liver tolerability and biomarker signals, while also discussing the potential of AAV-SLB101 in gene therapy.
Read more →SLDBSolid Biosciences Present 2025 Neuromuscular Study Group Annual
Solid Biosciences Present 2025 Neuromuscular Study Group Annual
Read more →SLDBSolid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101
Solid Biosciences has entered a non-exclusive licensing agreement with Kinea Bio to utilize its proprietary capsid AAV-SLB101 for the development of KNA-155, a gene therapy targeting dysferlin-related limb-girdle muscular dystrophy. Solid will receive an upfront payment and potential royalties based on sales milestones. AAV-SLB101 has demonstrated enhanced muscle tropism and reduced liver biodistribution in preclinical studies.
Read more →SLDBSolid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates
Read more →SLDBSolid Biosciences Receives FDA Fast Track Designation for SGT-501 First in Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia CPVT
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First in Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia CPVT
Read more →SLDBSolid Biosciences Announces FDA IND and Health Canada CTA Approval for First in Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia CPVT
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First in Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia CPVT
Read more →SLDBSolid Biosciences to Participate at the Jefferies Global Healthcare Conference
Solid Biosciences Inc. will participate in the Jefferies Global Healthcare Conference on June 4, 2025, where President and CEO Bo Cumbo and Chief Medical Officer Gabriel Brooks will engage in a fireside chat. This event aims to showcase the company's efforts in developing precision genetic medicines targeting rare diseases. Additionally, institutional investors are invited to request meetings with the management during the conference for further discussions. Solid Biosciences emphasizes its patient-focused mission to improve the lives of patients suffering from serious conditions.
Read more →SLDBSolid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates
Read more →SLDBSolid Biosciences to Participate at The Citizens Life Sciences Conference
Solid Biosciences Inc. will have its President and CEO, Bo Cumbo, participate in a fireside chat at The Citizens Life Sciences Conference on May 7, 2025. The event aims to provide insights into the company’s advancements in precision genetic medicines for neuromuscular and cardiac diseases. A live webcast of the discussion will be available, with a replay accessible for 30 days. Additionally, institutional investors are encouraged to connect with management during the conference.
Read more →SLDBSolid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting
Solid Biosciences Inc. (Nasdaq: SLDB) will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003 at the upcoming ASGCT Annual Meeting. The company highlights significant advances in gene therapy for Duchenne muscular dystrophy, showcasing initial safety, expression, and biomarker data. Presentations will cover various aspects of their innovative therapy, emphasizing their commitment to develop effective genetic medicines for rare neuromuscular and cardiac conditions. The meeting will occur from May 13-17, 2025, in New Orleans, LA.
Read more →SLDBSolid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Solid Biosciences Inc. is set to present findings from its Phase 1/2 INSPIRE DUCHENNE trial at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. The trial evaluates SGT-003, a next-generation gene therapy targeting Duchenne muscular dystrophy. This investigational gene therapy includes a unique microdystrophin construct and shows potential in addressing key symptoms of the disease. The event will take place in Dallas, TX from March 16-19, 2025.
Read more →SLDBSolid Biosciences Present 2025 Muscular Dystrophy Association
Solid Biosciences Present 2025 Muscular Dystrophy Association
Read more →SLDBSolid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Read more →SLDBSolid Biosciences Announces Pricing of Underwritten Offering
Solid Biosciences Inc. has announced the pricing of an underwritten offering of approximately 35.7 million shares of its common stock at $4.03 per share, alongside pre-funded warrants for an expected total of $200 million in gross proceeds. The offering includes notable investors such as Adage Capital Partners and Bain Capital Life Sciences. The closing is anticipated on or about February 19, 2025, pending customary conditions. The company specializes in developing precision genetic medicines for neuromuscular and cardiac diseases.
Read more →SLDBSolid Biosciences Reports Positive Initial Clinical Data from Next Generation Duchenne Gene Therapy Candidate SGT-003
Solid Biosciences Reports Positive Initial Clinical Data from Next Generation Duchenne Gene Therapy Candidate SGT-003
Read more →SLDBFebruary 2025 SGT-003 INSPIRE DUCHENNE DATA UPDATE 2025 Solid Biosciences Cautionary Note Regarding Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Sec
Solid Biosciences provided an update on SGT-003 in the INSPIRE Duchenne trial, discussing advancements and ongoing clinical data as of February 2025. The presentation highlighted that six participants have been dosed with no serious adverse events reported. Promising results include localized nNOS activity in muscle fibers, but caution was advised regarding future expectations and potential risks in clinical and regulatory pathways. The company anticipates further updates as more participants are dosed throughout the year.
Read more →SLDBSolid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich s Ataxia
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich s Ataxia
Read more →SLDBSolid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines
Read more →SLDBSolid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Solid Biosciences Inc. announced that its President and CEO, Bo Cumbo, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The company's focus is on developing precision genetic medicines to treat neuromuscular and cardiac diseases, with various gene therapy candidates in its pipeline. A live webcast of the presentation will be available, and there are opportunities for institutional investors to meet with the company's management during the event. Solid aims to improve the quality of life for patients affected by these diseases.
Read more →SLDBSolid Biosciences Announces FDA IND Clearance for First In Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich s At
Solid Biosciences Announces FDA IND Clearance for First In Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich s At
Read more →SLDBSolid Biosciences Added to the Nasdaq Biotechnology Index
Solid Biosciences Added to the Nasdaq Biotechnology Index
Read more →SLDBSolid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
Read more →SLDBSolid Biosciences to Present at the Jefferies London Healthcare Conference
Solid Biosciences Inc. announced that its President and CEO, Bo Combo, along with Chief Medical Officer Gabriel Brooks, will present at the Jefferies London Healthcare Conference on November 20, 2024. The company, which specializes in precision genetic medicines for neuromuscular and cardiac diseases, is keen to engage with institutional investors during the event. A live webcast of the presentation will be available, along with a replay for 30 days. This conference marks an important opportunity for Solid Biosciences to showcase its advancements in gene therapy.
Read more →SLDBSolid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
Read more →SLDBSolid Biosciences to Participate at the Truist Securities BioPharma Symposium
Solid Biosciences Inc. announced that Dr. Gabriel Brooks, its Chief Medical Officer, will participate in the Genetic Medicine Panel at the Truist Securities BioPharma Symposium on November 7, 2024, in New York. This event presents an opportunity for the company to engage with institutional investors and discuss advancements in its pipeline, which includes gene therapy candidates for various cardiac and neuromuscular diseases. Solid's commitment to improving patient outcomes in these areas is evident in its diverse portfolio and mission-driven approach.
Read more →SLDBSolid Biosciences Participate Truist Securities Biopharma
Solid Biosciences Participate Truist Securities Biopharma
Read more →SLDBSolid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference
Solid Biosciences Inc. (Nasdaq: SLDB) announced that its President and CEO Bo Cumbo, alongside Chief Medical Officer Gabriel Brooks, will participate in a fireside chat at Chardan's 8th Annual Genetic Medicines Conference on September 30, 2024. The conference will focus on advancements in genetic medicines for neuromuscular and cardiac diseases, showcasing the company's dedication to improving patient lives. A live webcast of the chat will be available, with a replay accessible for 30 days thereafter. The company has several gene therapy candidates and is actively engaged with institutional investors.
Read more →SLDBSolid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
Solid Biosciences Inc. will participate in the 2024 Cantor Global Healthcare Conference, highlighting its commitment to engaging with investors and stakeholders. Bo Cumbo, the President and CEO, along with Dr. Gabriel Brooks, the Chief Medical Officer, will be featured in a fireside chat. The event is scheduled for September 18, 2024, and will be accessible via live webcast, ensuring a broad audience reach. This participation underscores Solid's efforts to advance its gene therapy candidates for neuromuscular and cardiac diseases.
Read more →SLDBSolid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates
Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates
Read more →SLDBSolid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc. has granted 86,665 restricted stock units (RSUs) to four newly hired employees as part of its 2024 Inducement Stock Incentive Plan, following Nasdaq Listing Rule 5635(c)(4). One employee also received an option to buy 100,000 shares of common stock, vesting over four years. These grants aim to enhance the company's ability to attract and retain talent while advancing its pipeline of genetic therapies for serious diseases, including Duchenne muscular dystrophy and cardiac conditions.
Read more →SLDBSolid Biosciences Reports Inducement Grant Under Nasdaq Listing
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing
Read more →SLDBSolid Biosciences Joins the Russell 3000 Index
Solid Biosciences Joins the Russell 3000 Index
Read more →SLDBSolid Biosciences Provides First Quarter 2024 Business Update and Financial Results
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
Read more →SLDBSolid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
Solid Biosciences Inc. is set to present its advancements in gene therapy at the upcoming American Society of Gene and Cell Therapy Annual Meeting. The presentations will showcase improvements in AAV manufacturing, purification methods, and updates on the lead SGT-003 program, focusing on its potential in treating Duchenne muscular dystrophy. CEO Bo Cumbo expressed enthusiasm about sharing the company's scientific findings and innovations. These developments indicate Solid's commitment to addressing unmet medical needs in neuromuscular and cardiac diseases.
Read more →SLDBSolid Biosciences Present American Society Gene And Cell
Solid Biosciences Present American Society Gene And Cell
Read more →SLDBSolid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Read more →SLDBSolid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
Solid Biosciences Inc. has announced that its President and CEO Bo Cumbo, alongside CMO Gabriel Brooks, will present at the upcoming Cantor's Virtual Muscular Dystrophy Symposium set for April 2, 2024. The company aims to highlight its advancements in gene therapy candidates targeting rare neuromuscular and cardiac diseases. This presentation underscores Solid Biosciences' commitment to improving the lives of patients affected by such conditions through innovative treatments.
Read more →SLDBSolid Biosciences Participate Cantors Virtual Muscular Dystrophy
Solid Biosciences Participate Cantors Virtual Muscular Dystrophy
Read more →SLDBSolid Biosciences Provides Fourth Quarter And Full Year 2023
Solid Biosciences Provides Fourth Quarter And Full Year 2023
Read more →SLDBSolid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV SLB101 a Proprietary Muscle Targeted Capsid in the Development of an RNAi Therapy to treat FSHD
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV SLB101 a Proprietary Muscle Targeted Capsid in the Development of an RNAi Therapy to treat FSHD
Read more →SLDBSolid Biosciences Granted FDA Orphan Drug Designation Duchenne
Solid Biosciences Granted FDA Orphan Drug Designation Duchenne
Read more →SLDBForward Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and
Solid Biosciences presented forward-looking statements regarding its future expectations at the 42nd Annual J.P. Morgan Healthcare Conference in January 2024. The company discussed its advancement in clinical trials for its product candidates SGT-003 and SGT-501, with expected milestones and potential benefits, particularly for Duchenne Muscular Dystrophy. However, various risks and uncertainties were highlighted, including regulatory approvals and competition within the biopharma sector.
Read more →SLDBSolid Biosciences Announces 109 Million Private Placement
Solid Biosciences Announces 109 Million Private Placement
Read more →SLDBSolid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference
Solid Biosciences Inc. announced that its CEO, Bo Cumbo, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The company focuses on developing precision genetic medicines for various neuromuscular and cardiac diseases, featuring multiple gene therapy candidates. The conference will provide an opportunity for institutional investors to engage with company management. A live webcast of the presentation will also be available for broader audience access.
Read more →SLDBSolid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003
Solid Biosciences has announced that its Duchenne muscular dystrophy gene therapy candidate, SGT-003, has received Fast Track Designation from the FDA. This designation aims to facilitate its expedited development due to the high unmet needs in the Duchenne community. Following the recent IND clearance for SGT-003, a Phase 1/2 trial will begin to assess its safety and tolerability in pediatric patients. The company emphasizes its commitment to developing a potentially life-changing therapy while collaborating closely with the FDA throughout the process.
Read more →SLDBSolid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference
Solid Biosciences Inc. announced that its CEO, Bo Cumbo, will present at the 35th Annual Piper Sandler Healthcare Conference on November 30, 2023. The company specializes in precision genetic medicines for neuromuscular and cardiac diseases. Interested institutional investors can schedule meetings with the management team during the conference. Solid Biosciences is focused on advancing a pipeline of gene therapy candidates aimed at treating serious conditions such as Duchenne muscular dystrophy and various cardiac diseases.
Read more →SLDBSolid Biosciences Participate 35th Annual Piper Sandler
Solid Biosciences Participate 35th Annual Piper Sandler
Read more →SLDBSolid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Solid Biosciences has received FDA clearance for its investigational new drug application for SGT-003, a gene therapy candidate targeting Duchenne muscular dystrophy. The company plans to initiate a Phase 1/2 trial focusing on pediatric patients aged 4 to under 6 years. SGT-003 utilizes a differentiated delivery method that aims for improved safety and efficacy in treatment. The initiative is considered a significant step toward addressing the pressing needs within the Duchenne community.
Read more →SLDBSolid Biosciences to Participate at Jefferies London Healthcare Conference
Solid Biosciences Inc. will present at the Jefferies London Healthcare Conference on November 15, 2023, at 5:00 pm GMT. CEO Bo Cumbo will represent the company, showcasing its focus on precision genetic medicines for neuromuscular and cardiac diseases. Investors interested in dialogue with management are encouraged to contact their Jefferies representatives. Solid's ongoing efforts include the development of therapies for conditions like Duchenne muscular dystrophy and catecholaminergic polymorphic ventricular tachycardia.
Read more →SLDBSolid Biosciences Participate Jefferies London Healthcare
Solid Biosciences Participate Jefferies London Healthcare
Read more →SLDBSolid Biosciences Provides Third Quarter Business Update And
Solid Biosciences Provides Third Quarter Business Update And
Read more →SLDBSolid Biosciences Appoints Gabriel Brooks M.D. Chief Medical
Solid Biosciences Appoints Gabriel Brooks M.D. Chief Medical
Read more →SLDBSolid Biosciences Appoints Gabriel Brooks M D as Chief Medical Officer
Solid Biosciences Appoints Gabriel Brooks M D as Chief Medical Officer
Read more →SLDBSolid Biosciences to Participate in Citi’s 18th Annual BioPharma Conference
Solid Biosciences Inc. has announced its participation in the Citi 18th Annual BioPharma Conference, scheduled for September 7, 2023. Bo Cumbo, the company’s CEO, will present at the event. A live webcast of the presentation will be available for investors, and a replay will be accessible for 30 days post-event. Solid Biosciences is focused on creating genetic therapies for neuromuscular and cardiac diseases, including several promising programs.
Read more →SLDBSolid Biosciences Participate Citis 18th Annual Biopharma
Solid Biosciences Participate Citis 18th Annual Biopharma
Read more →SLDBSolid Biosciences Provides Second Quarter Business Update and Financial Results
Solid Biosciences Provides Second Quarter Business Update and Financial Results
Read more →SLDBSolid Biosciences to Participate at the Jefferies Healthcare Conference
Solid Biosciences Inc. announced its participation in the Jefferies Healthcare Conference on June 8, 2023, where CEO Bo Cumbo will host a fireside chat. An online webcast of the discussion will be available for interested parties. The company, focused on developing genetic medicines for neuromuscular and cardiac diseases, aims to connect with institutional investors at the event.
Read more →SLDBSolid Biosciences Participate Jefferies Healthcare Conference
Solid Biosciences Participate Jefferies Healthcare Conference
Read more →SLDBSolid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit
Solid Biosciences Inc. announced that Bo Cumbo, its CEO, will participate in a fireside chat at the Barclays Gene Editing & Therapy Summit on May 24, 2023. This event provides an opportunity for investors to gain insights into the company’s direction in developing genetic medicines for neuromuscular and cardiac diseases. The company will also make a live webcast of the chat available for interested parties. Solid is focused on advancing treatments for conditions such as Duchenne muscular dystrophy and Friedreich's Ataxia.
Read more →SLDBSolid Biosciences Present American Society Gene And Cell Therapy
Solid Biosciences Present American Society Gene And Cell Therapy
Read more →SLDBSolid Biosciences Provides First Quarter Business Update And
Solid Biosciences Provides First Quarter Business Update And
Read more →SLDBSolid Biosciences Present Jmp Securities Life Sciences
Solid Biosciences Present Jmp Securities Life Sciences
Read more →SLDBSolid Biosciences to Present at JMP Securities Life Sciences Conference
Solid Biosciences Inc. announced that its CEO, Bo Cumbo, will present at the JMP Securities Life Sciences Conference on May 15, 2023. This appearance will introduce their ongoing projects, particularly in the fields of neuromuscular and cardiac diseases. A live webcast of the presentation will be available, as well as a recorded replay for later access. The company aims to improve the lives of patients suffering from Duchenne and other conditions through innovative genetic therapies.
Read more →SLDBSolid Biosciences Participate Chardans 7th Annual Genetic
Solid Biosciences Participate Chardans 7th Annual Genetic
Read more →SLDBSolid Biosciences to Participate in Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Solid Biosciences Inc. will take part in Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 24, 2023. The event will feature a fireside chat with company management, aimed at discussing advancements in genetic medicines. A live webcast of the discussion will be accessible on the Company's website, allowing broader participation. The company continues to focus on developing treatments for neuromuscular and cardiac diseases.
Read more →SLDBSolid Biosciences Present 22nd Annual Needham Healthcare
Solid Biosciences Present 22nd Annual Needham Healthcare
Read more →SLDBSolid Biosciences to Present at the 22nd Annual Needham Healthcare Conference
Solid Biosciences Inc. will present at the 22nd Annual Needham Healthcare Conference on April 20, 2023. CEO Bo Cumbo is set to present at 8:00 AM ET, followed by a gene therapy panel discussion later that day. A live webcast of the presentation will be available, enhancing transparency for investors. This participation highlights the company's commitment to advancing genetic medicines for neuromuscular and cardiac diseases.
Read more →SLDBSolid Biosciences Provides Fourth Quarter And Full Year 2022
Solid Biosciences Provides Fourth Quarter And Full Year 2022
Read more →SLDBSolid Biosciences Participate Bmo Biopharma Spotlight Series
Solid Biosciences Participate Bmo Biopharma Spotlight Series
Read more →SLDBSolid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery
Solid Biosciences Inc. announced the participation of its CEO, Bo Cumbo, in the BMO Biopharma Spotlight Series focusing on genetic medicine delivery. He will discuss innovative AAVs targeting diverse tissues in a panel set for March 28, 2023. The event will be exclusive to BMO clients, with a replay also available on the company's website. Solid Biosciences is committed to developing therapies for neuromuscular and cardiac diseases.
Read more →SLDBSOLID BIO SCIENCES IGNITE DMD Phase I/II Study of SGT-001 Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy Roxana Donisa Dreghici1, J. Patrick Gonzalez1, Kristy J. Brown1, Carl A. Morris1, Perry Shieh2, Barry
The Phase I/II IGNITE DMD study by Solid Biosciences is assessing the gene therapy SGT-001 for Duchenne Muscular Dystrophy (DMD). Results show positive changes in motor and pulmonary function at the one-year mark, with all subjects completing this time point and no new treatment-associated adverse events noted after the initial 90 days. Despite some serious adverse events reported, the study indicates promising outcomes for further trials. Solid Biosciences is also moving forward with the next-generation SGT-003 program, which is currently in IND-enabling studies.
Read more →SLDBSolid Biosciences to Present at Barclays Global Healthcare Conference
Solid Biosciences to Present at Barclays Global Healthcare Conference
Read more →SLDBSolid Biosciences Present Svb Securities Global Biopharma
Solid Biosciences Present Svb Securities Global Biopharma
Read more →SLDBSolid Biosciences to Present at SVB Securities Global Biopharma Conference
Solid Biosciences Inc. announced that CEO Bo Cumbo will present at the SVB Securities Global Biopharma Conference on February 15, 2023. The event aims to showcase the company's advancements in genetic medicines for neuromuscular and cardiac diseases. Investors can access a live webcast of the presentation and request meetings with the management team during the conference. Solid's commitment to developing treatments for debilitating conditions could attract further interest from institutional investors.
Read more →SLDBSolid Tumor Testing Market Worth USD 59.45 Bn by 2029 Recent trends, mergers and acquisitions, region-wise growth analysis along with challenges
The Solid Tumor Testing Market is projected to experience significant growth, expanding from USD 32.48 billion in 2021 to USD 59.45 billion by 2029, reflecting a CAGR of 7.85%. This growth is attributed to technological advancements, an increase in cancer cases, and the rising demand for improved diagnostic testing methodologies such as next-generation sequencing and immunohistochemistry. Major players are leveraging strategies like acquisitions and partnerships to enhance their market positions. The North American market is anticipated to dominate during the forecast period due to its advanced healthcare infrastructure and research capabilities.
Read more →SLDBSolid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases
Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases
Read more →SLDBSolid Biosciences Outlines Strategy Leadership Precision Genetic
Solid Biosciences Outlines Strategy Leadership Precision Genetic
Read more →SLDBSolid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases
Solid Biosciences has outlined its strategic priorities for 2023, focusing on advancing its pipeline of genetic medicines for neuromuscular and cardiac diseases. Key highlights include the expected IND application for SGT-003 for Duchenne muscular dystrophy and ongoing development of AVB-202 for Friedreich's Ataxia. The company enters 2023 with significant financial resources, which are projected to support its goals into 2025. Additionally, the appointment of Kevin Tan as Chief Financial Officer aims to bolster execution of their corporate strategy.
Read more →SLDBSolid Biosciences Present 41st Annual JP Morgan Healthcare
Solid Biosciences Present 41st Annual JP Morgan Healthcare
Read more →SLDBSolid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer
Solid Biosciences Inc. has announced an inducement grant to its newly appointed Chief Financial Officer and Treasurer, Kevin Tan. The inducement includes an option to purchase 90,000 shares of common stock and a restricted stock unit award of 45,000 shares. The grants aim to support Mr. Tan's transition into the role, with a vesting schedule that encourages long-term commitment to the company. This move reflects Solid Biosciences' strategy to strengthen its leadership team as it continues to develop genetic medicines for neuromuscular and cardiac diseases.
Read more →SLDBSolid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer
Solid Biosciences Inc. has appointed Kevin Tan as Chief Financial Officer, bringing over 20 years of experience in the biopharmaceutical industry. His prior roles include CFO at Selecta Biosciences and Treasurer at Sarepta Therapeutics, where he developed strong financial and strategic skills. Tan expressed excitement about joining the management team and indicated confidence in the company's financial position to drive value in the future.
Read more →SLDBSolid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Solid Biosciences Inc. will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023. Bo Cumbo, the company's CEO, will represent Solid, providing insights into their genetic medicines for neuromuscular and cardiac diseases. The event underscores the company's commitment to advancing their innovative programs aimed at improving patient lives.
Read more →SLDBSolid Biosciences Appoints Kevin Tan CFA Chief Financial Officer
Solid Biosciences Appoints Kevin Tan CFA Chief Financial Officer
Read more →SLDBSolid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement - Transactions create a precision genetic medicine company focused on neuromuscular and cardiac diseases, led
Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement - Transactions create a precision genetic medicine company focused on neuromuscular and cardiac diseases, led by industry veteran Bo Cumbo - - Company to leverage syner
Read more →SLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing
Read more →SLDBSOLID BIOSCIENCES INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this Amended and Restated 2020 Equity Incentive Plan (the Plan ) of Solid Biosciences Inc., a Delaware corporation (the Com
SOLID BIOSCIENCES INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN The purpose of this Amended and Restated 2020 Equity Incentive Plan (the Plan ) of Solid Biosciences Inc., a Delaware corporation (the Company ), is to advance the interests of the Company s stockholders by
Read more →SLDBSolid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio
- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases - CHARLESTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for D
Read more →SLDBSolid Biosciences Announces Stockholder Approval Acquisition
Solid Biosciences Announces Stockholder Approval Acquisition
Read more →SLDBSolid Biosciences to Participate at the Piper Sandler 34th Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Foun
Read more →SLDBSolid Biosciences Participate Piper Sandler 34th Annual
Solid Biosciences Participate Piper Sandler 34th Annual
Read more →SLDBSolid Biosciences Provides Third Quarter 2022 Business Update and Financial Results
Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results
Read more →SLDBSolid Biosciences Announces a 1 for 15 Reverse Stock Split
Solid Biosciences Announces a 1 for 15 Reverse Stock Split
Read more →SLDBSolid Biosciences Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle
- AAV-SLB101 is the capsid used in SGT-003, Solid’s next-generation Duchenne gene therapy, expected to enter the clinic in late-2023 - - Additional novel capsids based on AAV-SLB101 binding protein data are also under evaluation and offer potential to improve safety and efficacy
Read more →SLDBSolid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating Improvements in Ambulatory Function
Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating Improvements in Ambulatory Function
Read more →SLDBSolid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement - Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by
Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement - Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo - -
Read more →SLDBSolid Biosciences Business Update Call
Business Update Call Caitlin Lowie - VP, Communications and IR, Solid Biosciences Ilan Ganot - Co-Founder, President and CEO, Solid Biosciences Bo Cumbo - President, Chief Executive Officer of AavantiBio Carl Morris - Chief Financial Officer, Solid Biosciences Jenny Marlow -
Read more →SLDBSolid Biosciences Provides Second Quarter 2022 Business Update and Financial Results - Transition to transient transfection-based manufacturing process continues for SGT-001; Company expects to continue dosing patients i
Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results - Transition to transient transfection-based manufacturing process continues for SGT-001; Company expects to continue dosing patients in 2023 - - Development of next-generation Duchenne gene t
Read more →SLDBSolid Biosciences Present Upcoming Scientific And Patient
Solid Biosciences Present Upcoming Scientific And Patient
Read more →SLDBSolid Biosciences to Present at Upcoming Scientific and Patient Advocacy Conferences
CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate in the following upcoming sci
Read more →SLDBSolid Biosciences Reports Inducement Grant to New Senior Vice President, Quality
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vi
Read more →SLDBSolid Biosciences Reports Inducement Grant New Senior Vice
Solid Biosciences Reports Inducement Grant New Senior Vice
Read more →SLDBSolid Biosciences to Present at ASGCT 25th Annual Meeting and CureDuchenne 2022 FUTURES National Conference
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate in the following upcoming scie
Read more →SLDBSolid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy - IGNITE DMD functional and durability patient data support advancemen
Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy - IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scal
Read more →SLDBSolid Biosciences Management Host Call April 27 2022 Discuss
Solid Biosciences Management Host Call April 27 2022 Discuss
Read more →SLDBSolid Biosciences Management to Host Call on April 27, 2022 to Discuss Updated Corporate Strategy and First Quarter 2022 Financial Results
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2022 financial results befo
Read more →SLDBSolid Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and 2 Year Efficacy and Safety Data from the Ongoing Phase I II IGNITE DMD Clinical Trial of SGT-001
Solid Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and 2 Year Efficacy and Safety Data from the Ongoing Phase I II IGNITE DMD Clinical Trial of SGT-001
Read more →SLDBSolid Biosciences Participate Svb Leerink 11th Annual Global
Solid Biosciences Participate Svb Leerink 11th Annual Global
Read more →SLDBSolid Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Operating Officer, and Carl Mor
Read more →SLDBSolid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates - Continue to advance SGT-001 by dosing additional patients in IGNITE DMD - - Advance next-generation Duchenne gene therapy pro
Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates - Continue to advance SGT-001 by dosing additional patients in IGNITE DMD - - Advance next-generation Duchenne gene therapy program (SGT-003) to IND submission; SGT-003 has demonstrated
Read more →SLDBSolid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Foun
Read more →SLDBSolid Biosciences Present 40th Annual JP Morgan Healthcare
Solid Biosciences Present 40th Annual JP Morgan Healthcare
Read more →SLDBSolid Biosciences Reports Inducement Grant to New Senior Vice President Human Resources
Solid Biosciences Reports Inducement Grant to New Senior Vice President Human Resources
Read more →SLDBSolid Biosciences Provides Third Quarter 2021 Business Update and Financial Results
Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results
Read more →SLDBSolid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Co-Founder, President and Chief Executive Offi
Read more →SLDBSolid Biosciences Participate Jefferies Gene Therapyediting
Solid Biosciences Participate Jefferies Gene Therapyediting
Read more →SLDBSolid Biosciences And Forge Biologics Announce Viral Vector
Solid Biosciences And Forge Biologics Announce Viral Vector
Read more →SLDBSolid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
- Improvements in two additional assessments of pulmonary function in treated patients compared with untreated control patients further support potential functional benefit of SGT-001 one-year post administration - - Data presented at the Child Neurology Society 50th Annual Meet
Read more →SLDBSolid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
- Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital Capacity (FVC) - - Patient reported outcomes showed sustained improvements at
Read more →SLDBSolid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
- Functional and patient-reported outcomes data for the first three patients in the high-dose (2E14 vg/kg) cohort (Patients 4-6) 1.5 years post-dosing to be presented at the World Muscle Society 2021 Virtual Congress - CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Solid B
Read more →SLDBSolid Biosciences Provide Update Long Term Outcomes Data
Solid Biosciences Provide Update Long Term Outcomes Data
Read more →SLDBSolid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021
- Chief Operating Officer to discuss company’s advanced AAV gene therapy manufacturing capabilities and best practices for orphan drug development - CAMBRIDGE, Mass., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on adva
Read more →SLDBSolid Biosciences Reports Inducement Grant to New Senior Vice President, Finance
CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vi
Read more →SLDBSolid Biosciences Announces Appointment of Michael Inbar, CPA, MBA, as Senior Vice President, Finance
CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Michael Inbar, CPA, MBA, has joined the Company as Senior
Read more →SLDBSolid Biosciences Announces Appointment Michael Inbar CPA MBA
Solid Biosciences Announces Appointment Michael Inbar CPA MBA
Read more →SLDBSolid Biosciences Provides Second Quarter 2021 Business Update and Financial Results - Clinical activities underway to advance patient dosing in IGNITE DMD; next patient dosing anticipated in Q4 2021 - - Development acti
Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results - Clinical activities underway to advance patient dosing in IGNITE DMD; next patient dosing anticipated in Q4 2021 - - Development activities continue for pipeline initiatives SGT-003 and Ultra
Read more →SLDBSolid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development
CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Senior
Read more →SLDBSolid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular Dystrophy
Solid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular Dystrophy
Read more →SLDBThe 2020 Stock Incentive Plan (the Plan ) of Solid Biosciences Inc.
2020 STOCK INCENTIVE PLAN The 2020 Stock Incentive Plan (the Plan ) of Solid Biosciences Inc. is hereby amended as follows: 1. Section 4(a)(1)(A) of the Plan is hereby deleted and a new Section 4(a)(1)(A) is inserted in lieu thereof which shall read as (A) 10,000,000 shares of
Read more →SLDBSolid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer
CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Dr. Iman Barilero has joined the Company as Chief Regulato
Read more →SLDBSolid Biosciences Reports Inducement Grant to New Chief Regulatory Officer
Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer
Read more →SLDBSolid Biosciences Announces Appointment Iman Barilero Pharmd Phd
Solid Biosciences Announces Appointment Iman Barilero Pharmd Phd
Read more →SLDBSolid Biosciences to Present at the Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Operating Officer, will present
Read more →SLDBSolid Biosciences Present Jefferies Virtual Healthcare
Solid Biosciences Present Jefferies Virtual Healthcare
Read more →SLDBSolid Biosciences Present Upcoming Scientific Conferences
Solid Biosciences Present Upcoming Scientific Conferences
Read more →SLDBSolid Biosciences to Present at Upcoming Scientific Conferences
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate at the following upcoming scie
Read more →SLDBSolid Biosciences Provides First Quarter 2021 Business Update and Financial Results - Patients 7 and 8 dosed in IGNITE-DMD Phase I/II clinical trial under new clinical protocol and second-generation SGT-001 manufacturing
Solid Biosciences Provides First Quarter 2021 Business Update and Financial Results - Patients 7 and 8 dosed in IGNITE-DMD Phase I/II clinical trial under new clinical protocol and second-generation SGT-001 manufacturing process; patient 8 experienced a serious adverse event -
Read more →SLDBSolid Biosciences Host First Quarter 2021 Financial Results And
Solid Biosciences Host First Quarter 2021 Financial Results And
Read more →SLDBSolid Biosciences to Host First Quarter 2021 Financial Results and Business Update Call on May 14, 2021
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2021 financial results before
Read more →SLDBSolid Biosciences Highlights Expertise AAV Gene Therapy Multiple
Solid Biosciences Highlights Expertise AAV Gene Therapy Multiple
Read more →SLDBSolid Biosciences Highlights Expertise in AAV Gene Therapy with Multiple Abstracts to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting
-Data from studies of novel AAV vectors and AAV immunology and an encore of 12-month safety, efficacy and patient-reported outcomes measurements from the ongoing IGNITE DMD trial of SGT001 to be presented- CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.
Read more →SLDBSolid Biosciences Participate Virtual Fireside Chat Chardan 5th
Solid Biosciences Participate Virtual Fireside Chat Chardan 5th
Read more →SLDBSolid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit
CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, Ph.D., Chief Operating Officer, and Louis
Read more →SLDBSolid Biosciences Participate Guggenheim Healthcare Talks
Solid Biosciences Participate Guggenheim Healthcare Talks
Read more →SLDBSolid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Carl Morris, Ph.D., Chief Scientific Officer, will partic
Read more →SLDBSolid Biosciences Announces Closing of Public Offering and Full Exercise of Over Allotment Option
Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over Allotment Option
Read more →SLDBSolid Biosciences Announces Pricing of Public Offering of Common Stock
Solid Biosciences Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Massachusetts, March 18, 2021 Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced t
Read more →SLDBSolid Biosciences Announces Pricing Public Offering Common Stock
Solid Biosciences Announces Pricing Public Offering Common Stock
Read more →SLDBSolid Biosciences Announces Proposed Public Offering of Common Stock
Solid Biosciences Announces Proposed Public Offering of Common Stock
Read more →SLDBSolid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg kg Cohort
Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg kg Cohort
Read more →SLDBSolid Biosciences Reports Positive Interim Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort - Interim data from six patients provide evidence o
Solid Biosciences Reports Positive Interim Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort - Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints
Read more →SLDBSolid Biosciences Reports Inducement Grant to New Chief Legal Officer
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Chief
Read more →SLDBSolid Biosciences Announces Appointments to Management Team and Board of Directors
Solid Biosciences Announces Appointments to Management Team and Board of Directors
Read more →SLDBEfficacy and Safety Data from Solid Biosciences Ongoing IGNITE DMD Phase I II Clinical Trial to be Presented at the 2021 MDA Clinical Scientific Conference
Efficacy and Safety Data from Solid Biosciences Ongoing IGNITE DMD Phase I II Clinical Trial to be Presented at the 2021 MDA Clinical Scientific Conference
Read more →SLDBSolid Biosciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Technology Officer, and Cathryn
Read more →SLDBSolid Biosciences Present Upcoming Investor Conferences
Solid Biosciences Present Upcoming Investor Conferences
Read more →SLDBSolid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Foun
Read more →SLDBSolid Biosciences Present 39th Annual JP Morgan Healthcare
Solid Biosciences Present 39th Annual JP Morgan Healthcare
Read more →SLDBSolid Biosciences Announces $90 Million Private Placement Cambridge, MA
Solid Biosciences Announces $90 Million Private Placement Cambridge, MA December 11, 2020 - Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has entered i
Read more →SLDBSolid Biosciences Reports Third Quarter 2020 Financial Results and Provides Business Update IGNITE DMD clinical trial expected to resume dosing in the first quarter of 2021 -Collaboration with Ultragenyx creates opportun
Solid Biosciences Reports Third Quarter 2020 Financial Results and Provides Business Update IGNITE DMD clinical trial expected to resume dosing in the first quarter of 2021 -Collaboration with Ultragenyx creates opportunities to develop additional gene therapies for Duchene mus
Read more →SLDBSolid Biosciences Host Third Quarter 2020 Financial Results And
Solid Biosciences Host Third Quarter 2020 Financial Results And
Read more →SLDBSolid Biosciences to Host Third Quarter 2020 Financial Results and Business Update Call on November 5, 2020
CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release third quarter 2020 financial results befor
Read more →SLDBSolid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Jennifer Ziolkowski, Chief Financial Officer, Joel Schneid
Read more →SLDBSolid Biosciences Participate Virtual Fireside Chat Chardan 4th
Solid Biosciences Participate Virtual Fireside Chat Chardan 4th
Read more →SLDBSolid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial
Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial
Read more →SLDBSolid Biosciences Provides Update Regarding the IGNITE DMD Phase I II Clinical Hold
Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I II Clinical Hold
Read more →SLDBSOLID BIOSCIENCES INC. 2020 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this 2020 Equity Incentive Plan (the Plan ) of Solid Biosciences Inc., a Delaware corporation (the Company ), is to advance the interests of the
SOLID BIOSCIENCES INC. EQUITY INCENTIVE PLAN The purpose of this 2020 Equity Incentive Plan (the Plan ) of Solid Biosciences Inc., a Delaware corporation (the Company ), is to advance the interests of the Company s stockholders by enhancing the Company s ability to attract, re
Read more →SLDBSolid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of Directors
CAMBRIDGE, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced today the appointment of board member Ian F. Smith as Chairman of the Board. Mr.
Read more →SLDBSolid Biosciences Announces Appointment Ian F Smith Chairman
Solid Biosciences Announces Appointment Ian F Smith Chairman
Read more →SLDBSolid Biosciences Hold Virtual Annual Meeting Stockholders June
Solid Biosciences Hold Virtual Annual Meeting Stockholders June
Read more →SLDBSolid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16 2020
Solid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16 2020
Read more →SLDBSolid Biosciences Presents Data from Duchenne Muscular Dystrophy Gene Therapy Program at ASGCT 23rd Annual Meeting
Virtual oral presentation reviews interim clinical biomarker data for SGT-001 and provides data on expression and co-localization of microdystrophin and dystrophin associated proteins in patients in the IGNITE DMD trial Virtual poster presentation provides data characterizing no
Read more →SLDBSolid Biosciences Presents Data Duchenne Muscular Dystrophy Gene
Solid Biosciences Presents Data Duchenne Muscular Dystrophy Gene
Read more →SLDBSolid Biosciences Provides Update regarding SGT-001 Phase I II Clinical Hold on IGNITE DMD
Solid Biosciences Provides Update regarding SGT-001 Phase I II Clinical Hold on IGNITE DMD
Read more →SLDBSolid Biosciences Announces Appointment of Ian F Smith to its Board of Directors
Solid Biosciences Announces Appointment of Ian F Smith to its Board of Directors
Read more →SLDBSolid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Biopsy results from the third patient dosed at 2E14 vg/kg in the SGT-001 IGNITE DMD clinical trial provides furth
Solid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Biopsy results from the third patient dosed at 2E14 vg/kg in the SGT-001 IGNITE DMD clinical trial provides further support for continued development Solid continues to
Read more →SLDBSolid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001
Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001
Read more →SLDBSolid Biosciences Provides Data Update from SGT-001 Development Program
Solid Biosciences Provides Data Update from SGT-001 Development Program
Read more →SLDBSolid Biosciences Provides SGT-001 Program Update
Solid Biosciences Provides SGT-001 Program Update
Read more →SLDBSolid Biosciences Participate Chardan 3rd Annual Genetic
Solid Biosciences Participate Chardan 3rd Annual Genetic
Read more →SLDBSolid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced that Joel Schneider, PhD., Chief Technology Officer, will participate in a webcast question and answer session at the upcoming Chardan Annual Genetic Medicines Conference at
Read more →SLDBSolid Biosciences Announces Publication Highlighting Important
Solid Biosciences Announces Publication Highlighting Important
Read more →SLDBSolid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update Additional patient dosed at 2E14 vg/kg in second cohort of IGNITE DMD trial Study protocol amended to expedite clinical executi
Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update Additional patient dosed at 2E14 vg/kg in second cohort of IGNITE DMD trial Study protocol amended to expedite clinical execution of SGT-001 Recent $60M capital raise extends runway in
Read more →SLDBSolid Biosciences Announces $60 Million Private Placement with New and Existing Investors Cambridge, MA
Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors Cambridge, MA July 26, 2019 Solid Biosciences Inc. (Nasdaq: SLDB) today announced that it has entered into a securities purchase agreement with a select group of institutional investors an
Read more →SLDBSolid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update Dosing of SGT-001 initiated in second cohort of patients in the IGNITE DMD clinical trial at 2E14 vg/kg Clinical activities unde
Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update Dosing of SGT-001 initiated in second cohort of patients in the IGNITE DMD clinical trial at Clinical activities underway at additional study sites Cambridge, MA May 13, 2019 Solid Bios
Read more →SLDBSolid Biosciences Announces Upcoming Preclinical Data Presentations at The American Society of Gene and Cell Therapy Annual Meeting
Solid Biosciences Announces Upcoming Preclinical Data Presentations at The American Society of Gene and Cell Therapy Annual Meeting
Read more →SLDBSolid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update Activities underway to commence dosing of second cohort of patients in the IGNITE DMD clinical trial at 2E14 vg
Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update Activities underway to commence dosing of second cohort of patients in the IGNITE DMD clinical trial at 2E14 vg/kg of SGT-001 Cambridge, MA March 13, 2019 - Solid Biosci
Read more →SLDBSolid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy
Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy
Read more →SLDBForward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties. These forw
Solid Biosciences Ilan Ganot, Co-Founder, CEO and President January 2019 Exhibit 99.1 Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve a number of risks
Read more →SLDBSolid Biosciences to Present at the J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Ilan Ganot, Co-Founder, Chief Executive Officer and President of Solid Biosciences will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Januar
Read more →SLDBSolid Biosciences Present JP Morgan Healthcare Conference
Solid Biosciences Present JP Morgan Healthcare Conference
Read more →SLDBSolid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business Update Two Additional Patients Dosed With SGT-001 Gene Transfer in IGNITE DMD Clinical Trial Company Plans to Report Preliminary Result
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business Update Two Additional Patients Dosed With SGT-001 Gene Transfer in IGNITE DMD Clinical Trial Company Plans to Report Preliminary Results from IGNITE DMD in the First Quarter of 2019 Cambridge
Read more →SLDBSolid Biosciences to Present at the Credit Suisse Healthcare Conference
CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018 at 2:50 pm MT in Scottsdale, Arizona. The Credit Suisse H
Read more →SLDBSolid Biosciences to Present at the Chardan Genetic Medicines Conference
CAMBRIDGE, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will participate in a question and answer format presentation at the Chardan Capital Markets 2nd Annual Genetic Medicines Conference on Tuesday, October 9, 20
Read more →SLDBSolid Biosciences to Present at the Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Cell & Gene Meeting on the Mesa on Wednesday, October 3, 2018 at 3:30 pm PT in La Jolla, California. The Cell & Gene Meeting on the Mesa
Read more →SLDBSolid Biosciences Welcomes Sukumar Nagendran, M.D., To Its Board Of Directors
CAMBRIDGE, Mass., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Sukumar Nagendran, M.D., has been elected to its Board of Directors. Dr. Nagendran brings to Solid more than 30 years of experience in key functional areas, including g
Read more →SLDBSolid Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update - IGNITE DMD Phase I/II Clinical Trial Patient Screening Has Resumed - Cambridge, MA
Solid Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update - IGNITE DMD Phase I/II Clinical Trial Patient Screening Has Resumed - Cambridge, MA August 10, 2018 - Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the seco
Read more →SLDBSolid Biosciences Welcomes Industry Expert Dr. Martin Freed To Its Board Of Directors
Ilan Ganot, Co-Founder and CEO, Assumes Additional Role of President Gilad Hayeem, Co-Founder, President and Board Member, Retires to Pursue Other Activities CAMBRIDGE, Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that Martin Fre
Read more →SLDBSolid Biosciences Announces FDA Removes Clinical Hold SGT-001
Solid Biosciences Announces FDA Removes Clinical Hold SGT-001
Read more →SLDBSOLID BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB
NEW ORLEANS, May 18, 2018 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (Nasdaq:SLDB), if they pu
Read more →SLDBSolid Biosciences Announces New Preclinical Data at the American Society of Gene and Cell Therapy Annual Meeting
Solid Biosciences Announces New Preclinical Data at the American Society of Gene and Cell Therapy Annual Meeting
Read more →SLDBSolid Biosciences Announces Upcoming Preclinical Data Presentations
CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that new preclinical data from its Duchenne muscular dystrophy (DMD) programs, including its lead gene transfer candidate, SGT-001, will be presented at the 21st Annual Meeting
Read more →SLDBSOLID BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB
NEW ORLEANS, May 11, 2018 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit ag
Read more →SLDBSolid Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update - Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial - Cambridge, MA
Solid Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update - Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial - Cambridge, MA - May 10, 2018 - Solid Biosciences Inc. (NASDAQ:SLDB) today reported fi
Read more →SLDBSolid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy
Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy
Read more →SLDBSOLID BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB
NEW ORLEANS, April 13, 2018 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (NasdaqGS:SLDB), if the
Read more →SLDBSolid Biosciences Reports Full Year 2017 Financial Results and Provides Corporate Update - Company Continues To Work To Address Clinical Hold On IGNITE DMD - Cambridge, MA
Solid Biosciences Reports Full Year 2017 Financial Results and Provides Corporate Update - Company Continues To Work To Address Clinical Hold On IGNITE DMD - Cambridge, MA, March 29, 2018 - Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year
Read more →SLDBSOLID BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB
NEW ORLEANS, March 28, 2018 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit
Read more →SLDBSolid Biosciences Announces Clinical Hold On SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy
Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy
Read more →SLDBSolid Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option
CAMBRIDGE, Mass., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the “Company” or “SLDB”), announced today the closing of its initial public offering of 8,984,375 shares of its common stock, sold by the Company at a public offering price of $16.00 per sha
Read more →SLDBSolid Biosciences Announces Closing Initial Public Offering And
Solid Biosciences Announces Closing Initial Public Offering And
Read more →SLDBSolid Biosciences Announces Pricing of Initial Public Offering
Solid Biosciences Announces Pricing of Initial Public Offering
Read more →Competitive Position
How SLDB ranks across every disease it competes inCompetitive Position is a premium feature
See how SLDB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial